Who are the enemies? Inflammation and autoimmune mechanisms

European Heart Journal, Supplement

Volumn 4, Issue G, 2002, Pages

  Hjalmarson, A ^a   Fu, M ^a   Mobini, R ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoantibody; Autoimmune; Cardiomyopathy; Myocarditis

Indexed keywords

AUTOANTIBODY;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; HEART DILATATION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MYOCARDITIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRUS MYOCARDITIS;

EID: 0036828103     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90087-8     Document Type: Review

References (66)

1. Kawai C. From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future. Circulation 1999; 99: 1091-100.
2. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343: 1388-98.
3. Strauer BE, KandolfR, Mall G, et al. Update 2001. Myocarditis: Cardiomyopathy [in German]. Med Klin 2001; 96: 608-25.
4. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-2.
5. Dec GW Jr, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312: 885-90.
6. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1061-8.
7. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269-75.
8. McCarthy RE III, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (non-fulminant) myocarditis. N Engl J Med 2000; 342: 690-5.
9. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95: 2476-8.
10. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-7.
11. Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81: 922-8.
12. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999; 34: 177-80.
13. Gravanis MB, Stemby NH. Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med 1991; 115: 390-2.
14. Wolfgram LJ, Beisel KW, Herskowitz A, et al. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol 1986; 136: 1846-52.
15. Herskowitz A, Wolfgram LJ, Rose NR, et al. Coxsackievirus B3 murine myocarditis: A pathologic spectrum of myocarditis in genetically defined inbred strains. J Am Coll Cardiol 1987; 9: 1311-9.
16. Muir P, Nicholson F, Tilzey AJ, et al. Chronic relapsing pericarditis and dilated cardiomyopathy: Serological evidence of persistent enterovirus infection. Lancet 1989; 1: 804-7.
17. Weiss LM, Liu XF, Chang KL, et al. Detection of enteroviral RNA in idiopathic dilated cardiomyopathy and other human cardiac tissues. J Clin Invest 1992; 90: 156-9.
18. Schwaiger A, Umlauft F, Weyrer K, et al. Detection of enteroviral ribonucleic acid in myocardial biopsies from patients with idiopathic dilated cardiomyopathy by polymerase chain reaction. Am Heart J 1993; 126: 406-10.
19. Klein R, Maisch B, Kochsiek K, et al. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. Clin Exp Immunol 1984; 58: 283-92.
20. Schultheiss HP, Bolte HD. Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 1985; 17: 603-17.
21. Wolff PG, Kuhl U, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J 1989; 117: 1303-9.
22. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989; 64: 97-103.
23. Magnusson Y, Marullo S, Hoyer S, et al. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990; 86: 1658-63.
24. Wallukat G, Morwinski M, Kowal K, et al. Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: Beta-adrenergic agonism without desensitization. Eur Heart J 1991; 12(suppl D): 178-81.
25. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91: 1964-8.
26. Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: Pro-inflammatory antibodies in CM patients. Biochem Biophys Res Commun 1999; 259: 255-6.
27. Felix SB, Staudt A, Dorffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590-8.
28. Muller J, Wallukat G, Dandel M, et al. Immunoglubulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-91.
29. Gullestad L, Aass H, Fjeld J, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
30. Wallukat G, Muller J, Podlowski S, et al. Agonist-like beta-adrenoceptor antibodies in heart failure. Am J Cardiol 1999; 83: 75H-9H.
31. Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997; 29: 641-55.
32. Omerovic E, Bollano E, Andersson B, et al. Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 2000; 32: 271-80.
33. Matsui S, Fu ML, Hayase M, et al. Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic 2 receptor. J Cardiovasc Pharmacol 2001; 38(suppl 1): S43-9.
34. Matsui S, Fu M, Hayase M, et al. Beneficial effect of angiotensin-converting enzyme inhibitor on dilated cardiomyopathy induced by autoimmune mechanism against beta1-adrenoceptor. J Cardiovasc Pharmacol 2000; 36(suppl 2): S43-8.
35. Matsui S, Persson M, Fu HM, et al. Protective effect of bisoprolol on beta-1 adrenoceptor peptide-induced autoimmune myocardial damage in rabbits. Herz 2000; 25: 267-70.
36. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992; 326: 77-82.
37. Grunig E, Tasman JA, Kucherer H, et al. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998; 31: 186-94.
38. Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993; 87: 1854-65.
39. Charron P, Tesson F, Poirier O, et al. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 1999; 20: 1587-9
40. Bunemann M, Lee KB, Pals-Rylaarsdam R, et al. Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol 1999; 61: 169-92.
41. Carlquist JF, Hibbs JB, Edelman LS, et al. Coxsakie B3 myocarditis in mice, viral clearance and post-infectious mortality are not associated with inceased nitric oxide production [abstract]. Circulation 1996; 94: 1-568.
42. Neu N, Beisel KW, Traystman MD, et al. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol 1987; 138: 2488-92.
43. Malkiel S, Kuan AP, Diamond B. Autoimmunity in heart disease: Mechanisms and genetic susceptibility. Mol Med Today 1996; 2: 336-42.
44. Caforio AL, Goldman JH, Baig MK, et al. Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart 1997; 77: 62-7.
45. Anderson JL, Carlquist JF, Hammond EH. Deficient natural killer cell activity in patients with idiopathic dilated cardiomyopathy. Lancet 1982; 2: 1124-7.
46. Gerli R, Rambotti P, Spinozzi F, et al. Immunologic studies of peripheral blood from patients with idiopathic dilated cardiomyopathy. Am Heart J 1986; 112: 350-5.
47. Limas CJ. Autoimmunity in dilated cardiomyopathy and the major histocompatibility complex. Int J Cardiol 1996; 54: 113-6.
48. Marriott JB, Goldman JH, Keeling PJ, et al. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 1996; 75: 287-90.
49. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-22.
50. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000; 343: 37-49.
51. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344: 655-64.
52. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337: 562-6.
53. Rathmell JC, Townsend SE, Xu JC, et al. Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319-29.
54. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334: 676-82.
55. Nemazee D. Receptor selection in B and T lymphocytes. Annu Rev Immunol 2000; 18: 19-51.
56. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-74.
57. Ferrari I, Levin MJ, Wallukat G, et al. Molecular mimicry between the immunodominant ribosomal protein PO of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 1995; 59: 59-65.
58. Borda E, Pascual J, Cossio P, et al. A circulating IgG in Chagas' disease which binds to beta-adrenoceptors of myocardium and modulates their activity. Clin Exp Immunol 1984; 57: 679-86.
59. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91: 2504-7.
60. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997; 80: 15L-25L.
61. Sasayama S, Matsumori A, Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res 1999;42: 557-64.
62. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
63. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-82.
64. Noutsias M, Seeberg B, Schultheiss HP, et al. Expression of cell adhesion molecules in dilated cardiomyopathy: Evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124-31.
65. Damas JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure: Possible role of platelets and monocytes. Cardiovasc Res 2000; 45: 428-36.
66. Sasayama S, Okada M, Matsumori A. Chemokines and cardiovascular diseases. Cardiovasc Res 2000; 45: 267-9.